文 献8）Vishwanathan K, Sanchez-Simon I, Keam B, Penel N, de Miguel-Luken M, Weilert D, et al. A multicenter, phase I, pharmacokinetic study of osimertinib in cancer patients with normal renal function or severe renal impairment. Pharmacol Res Perspect 2020; 8: e00613.9）Hirashima T, Satouchi M, Hida T, Nishio M, Kato T, Sakai H, et al. Osimertinib for Japanese patients with T790M-positive advanced non-small-cell lung cancer: A pooled subgroup analysis. Cancer Sci 2019; 110: 2884-93.10）Fujiwara Y, Goto Y, Kanda S, Horinouchi H, Yamamoto N, Sakiyama N, et al. Efficacy and safety of osimertinib in a Japanese compassionate use program. Jpn J Clin Oncol 2017; 47: 625-9.11）Galvani E, Peters GJ, Giovannetti E. EGF receptor-targeted therapy in non-small-cell lung cancer: role of germline polymorphisms in outcome and toxicity. Future Oncol 2012; 8:1015-29.12）Tan Y, Cao K, Ren G, Qin Z, Zhao D, Li N, et al. Effects of the ABCB1 and ABCG2 polymorphisms on the pharmacokinetics of afatinib in healthy Chinese volunteers. Xenobiotica 2020; 50: 237-43.13）Lemos C, Giovannetti E, Zucali PA, Assaraf YG, Scheffer GL, van der Straaten T, et al. Impact of ABCG2 polymorphisms on the clinical outcome and toxicity of gefitinib in non-small-cell lung cancer patients. Pharmacogenomics 2011; 12: 159-70.1401）Soria JC, Ohe Y, Vansteenkiste J, Reungwetwattana T, Chewaskulyong B, Lee KH, et al. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. N Engl J Med 2017; 378: 113-25.2）Brown K, Comisar C, Witjes H, Maringwa J, de Greef R, Vishwanathan K, et al. Population pharmacokinetics and exposure-response of osimertinib in patients with non-small cell lung cancer. Br J Clin Pharmacol 2017; 83: 1216-26.3）Cross DA, Ashton SE, Ghiorghiu S, Eberlein C, Nebhan CA, Spitzler PJ, et al. AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer. Cancer Discov 2014; 4: 1046-61.4）Chen Z, Chen Y, Xu M, Chen L, Zhang X, To KK, et al. Osimertinib （AZD9291） enhanced the efficacy of chemotherapeutic agents in ABCB1- and ABCG2-overexpressing cells in vitro, in vivo, and ex vivo. Mol Cancer Ther 2016; 15: 1845-58.5）Rood JJM, van Haren MJ, Beijnen JH, Sparidans RW. Bioanalysis of EGFRm inhibitor osimertinib, and its glutathione cycle- and desmethyl metabolites by liquid chromatography-tandem mass spectrometry. J Pharm Biomed Anal 2020; 177: 112871.6）U.S. Department of Health and Human Services Food and Drug Administration, Bioanalytical Method Validation Guidance for Industry. [https://www.fda.gov/downloads/drugs/guidances/ucm070107.pdf (accessed 2020 October 30)]7）アストラゼネカ株式会社．Ⅶ. 薬物動態に関する項目．医薬品インタビューフォーム「タグリッソ錠」．2019年12月改訂（第7版）
元のページ ../index.html#154